Ergomed's co-development partner, Aeterna Zentaris, has announced two further licensing deals for Zoptrex.
On 1 July, Aeterna Zentaris signed an exclusive licence agreement with affiliates of Orient EuroPharma Co for its lead anti-cancer compound, Zoptrex, for the initial indication of endometrial cancer for Taiwan and nine countries in south-east Asia.
On 31 July 2016, Aeterna Zentaris signed a second exclusive licence agreement with Rafa Laboratories for Israel and the Palestine Territories.
These follow on from the 2014 exclusive licence agreement with Sinopharm A-Think Pharmaceuticals Co Ltd. In line with the Company's co-development agreement with Aeterna Zentaris, Ergomed will receive a portion of all revenues generated from the commercialisation of the product.
Zoptrex, a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer.
As the rate of death in the trial is lower than expected, Aeterna Zentaris now expects to complete the Phase 3 clinical trial by the end of the year with results following early in 2017, and, if the results of the trial warrant doing so, to file a new drug application for Zoptrex in the first half of 2017. Ergomed chief executive Dr. Miroslav Reljanovic said: "We are delighted that our partner, Aeterna Zentaris has now licensed Zoptrex in the important markets of China, Israel, Taiwan and south-east Asia.
"In line with our strategy at IPO, these deals mark an important milestone in our co-development partnership with Aeterna Zentaris and demonstrate the value of our hybrid business model."